Background pattern
SEVELAMER CARBONATE WINTHROP 800 MG FILM-COATED TABLETS

SEVELAMER CARBONATE WINTHROP 800 MG FILM-COATED TABLETS

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use SEVELAMER CARBONATE WINTHROP 800 MG FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Sevelamer Carbonate Winthrop 800 mg Film-Coated Tablets

sevelamer carbonate

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack and other information

  1. What is Sevelamer Carbonate Winthrop and what is it used for
  2. What you need to know before you take Sevelamer Carbonate Winthrop
  3. How to take Sevelamer Carbonate Winthrop
  4. Possible side effects
  5. Storage of Sevelamer Carbonate Winthrop
  1. Contents of the pack and further information

1. What is Sevelamer Carbonate Winthrop and what is it used for

Sevelamer Carbonate Winthrop contains sevelamer carbonate as the active substance. It binds to phosphate in the digestive tract and reduces the levels of phosphate in the blood.

This medicine is used to control hyperphosphataemia (high levels of phosphate in the blood) in:

  • adult patients on dialysis (a technique to clean the blood). It can be used in patients undergoing haemodialysis (using a machine to filter the blood) or peritoneal dialysis (where fluid is pumped into the abdomen and a body membrane filters the blood);
  • patients with chronic kidney disease (long-term) who are not on dialysis and have a serum (blood) phosphate level of 1.78 mmol/l or higher.

This medicine should be used with other treatments such as calcium and vitamin D supplements to prevent the development of bone disease.

High levels of phosphate in the blood can lead to hard deposits in the body called calcifications. These deposits can harden in the blood vessels and make it more difficult for the blood to be pumped around the body. High phosphate levels in the blood can also cause itching of the skin, red eyes, bone pain, and fractures.

2. What you need to know before you take Sevelamer Carbonate Winthrop

Do not take Sevelamer Carbonate Winthrop:

  • if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)
  • if you have low levels of phosphate in the blood (your doctor will check this for you)
  • if you have intestinal obstruction.

Warnings and precautions

Tell your doctor before taking Sevelamer Carbonate Winthrop:

  • if you have problems swallowing. Your doctor may prefer to prescribe Renvela powder for oral suspension for you
  • if you have problems with stomach and intestinal motility (movement)
  • if you have active inflammation of the intestine
  • if you have had major stomach or intestinal surgery
  • if you have severe inflammatory bowel disease.

Tell your doctor while you are taking Sevelamer Carbonate Winthrop:

  • if you experience severe abdominal pain, stomach or intestinal disorders, or blood in your stools (gastrointestinal bleeding). These symptoms can be due to sevelamer crystals depositing in the intestine. Contact your doctor, who will decide whether to continue treatment or not.

Additional treatments

Due to your kidney condition or dialysis treatment, you may:

  • have low or high levels of calcium in your blood. As this medicine does not contain calcium, your doctor may prescribe calcium supplement tablets
  • have low levels of vitamin D in your blood. Therefore, your doctor may monitor your vitamin D blood levels and prescribe a vitamin D supplement if necessary. If you do not take multivitamin supplements, your blood levels of vitamins A, E, K, and folic acid may also decrease, so your doctor may monitor these levels and prescribe vitamin supplements as necessary.
  • have altered bicarbonate levels in your blood and increased acidity in your blood and other body tissues. Your doctor should monitor your bicarbonate levels in your blood.

Special note for patients on peritoneal dialysis

You may develop peritonitis (infection of the abdominal fluid) associated with peritoneal dialysis. This risk may be reduced with careful use of sterile techniques during bag changes. You should inform your doctor immediately if you experience any new signs or symptoms of abdominal discomfort, abdominal swelling, abdominal pain, abdominal tenderness, or abdominal stiffness, constipation, fever, chills, nausea, or vomiting.

Children

Do not give this medicine to children under 6 years of age as the safety and efficacy have not been established in children (under 6 years of age).

Using Sevelamer Carbonate Winthrop with other medicines

Tell your doctor if you are taking, have recently taken, or might take any other medicines.

  • Sevelamer Carbonate Winthrop should not be taken at the same time as ciprofloxacin (an antibiotic).
  • If you are taking medicines for heart rhythm problems or for epilepsy, you should consult your doctor when taking Sevelamer Carbonate Winthrop.
  • The effects of medicines such as cyclosporin, mycophenolate mofetil, and tacrolimus (medicines used to suppress the immune system) may be reduced by Sevelamer Carbonate Winthrop. Your doctor will advise you if you are taking these medicines.
  • A low level of thyroid hormone has been observed rarely in certain individuals taking levothyroxine (used to treat low thyroid hormone levels) and Sevelamer Carbonate Winthrop. Therefore, your doctor may monitor your thyroid-stimulating hormone levels in your blood more closely.
  • Medicines to treat stomach acid and reflux in your stomach or oesophagus, such as omeprazole, pantoprazole, or lansoprazole, known as "proton pump inhibitors", may reduce the effectiveness of Sevelamer Carbonate Winthrop. Your doctor should monitor your phosphate levels in your blood.

Your doctor will check regularly for interactions between Sevelamer Carbonate Winthrop and other medicines.

In some cases, when Renvela needs to be taken with another medicine, your doctor may tell you to take this medicine 1 hour before or 3 hours after taking Renvela. Your doctor should also consider monitoring the levels of that medicine in your blood.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

The potential risk of Sevelamer Carbonate Winthrop during human pregnancy is unknown. Consult your doctor, who will decide whether you can continue treatment with Sevelamer Carbonate Winthrop.

It is unknown whether Sevelamer Carbonate Winthrop passes into breast milk and affects your baby. Consult your doctor, who will decide whether you can breast-feed your baby or not and whether it is necessary to interrupt treatment with Sevelamer Carbonate Winthrop.

Driving and using machines

Sevelamer Carbonate Winthrop is unlikely to affect your ability to drive or use machines.

Excipients

This medicine contains less than 1 mmol sodium (23 mg) per tablet; this is essentially "sodium-free".

3. How to take Sevelamer Carbonate Winthrop

Take this medicine exactly as your doctor has told you. Your doctor will decide on the dose based on your phosphate levels.

The recommended initial dose of this medicine for adults and elderly patients is one to two 800 mg tablets with each meal 3 times a day. Consult your doctor, pharmacist, or nurse if you are not sure.

Take Sevelamer Carbonate Winthrop after a meal or with food.

The tablets should be swallowed whole. Do not crush, chew, or break them.

Initially, your doctor will check your phosphate levels in your blood every 2-4 weeks and may adjust the dose of Sevelamer Carbonate Winthrop as needed to achieve an adequate phosphate level.

Continue with the diet that your doctor has prescribed for you.

If you take more Sevelamer Carbonate Winthrop than you should

In case of a possible overdose, contact your doctor immediately.

If you forget to take Sevelamer Carbonate Winthrop

If you miss a dose, it should be omitted, so that the next dose should be taken at the usual time with a meal. Do not take a double dose to make up for forgotten doses.

If you stop taking Sevelamer Carbonate Winthrop

Taking your treatment with Sevelamer Carbonate Winthrop is important to maintain an appropriate level of phosphate in your blood. Stopping treatment with Sevelamer Carbonate Winthrop would have significant consequences, such as calcification in the blood vessels. If you consider stopping your treatment with Sevelamer Carbonate Winthrop, contact your doctor or pharmacist first.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Constipation is a very common side effect. It can be an early symptom of intestinal obstruction. If you experience constipation, inform your doctor or pharmacist.

Some side effects can be serious. If you get any of the following side effects, seek medical attention immediately:

  • Allergic reaction (signs include rash, hives, swelling, difficulty breathing). This is a very rare side effect (may affect up to 1 in 10,000 patients).
  • Intestinal obstruction has been reported (signs include severe swelling, abdominal pain, bloating or cramps, severe constipation). The frequency is not known (cannot be estimated from the available data).
  • Rupture of the intestinal wall has been reported (signs include severe stomach pain, chills, fever, nausea, vomiting, or a tender or sensitive abdomen). The frequency is not known.
  • Severe inflammation of the large intestine has been reported (symptoms include severe abdominal pain, stomach or intestinal disorders, or blood in the stools [gastrointestinal bleeding]) and crystal deposits in the intestine. The frequency is not known.

Other side effects have been reported in patients taking Sevelamer Carbonate Winthrop:

Very common (may affect more than 1 in 10 patients):

  • vomiting,
  • upper abdominal pain,
  • nausea

Common (may affect up to 1 in 10 patients):

  • diarrhoea,
  • stomach pain,
  • indigestion,
  • flatulence

Frequency not known:

  • cases of itching,
  • rash,
  • slow intestinal movement (motility).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Sevelamer Carbonate Winthrop

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle and/or carton after EXP. The expiry date refers to the last day of the month shown.

Keep the bottle tightly closed to protect from moisture.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and further information

Composition of Sevelamer Carbonate Winthrop

  • The active substance is sevelamer carbonate. Each film-coated tablet contains 800 mg of sevelamer carbonate.
  • The other ingredients are microcrystalline cellulose, sodium chloride, zinc stearate, hypromellose (E464), diacetylated monoglycerides.

Appearance of the product and pack size

Sevelamer Carbonate Winthrop film-coated tablets are white to off-white oval tablets with "RV800" printed on one side. The tablets are packed in high-density polyethylene bottles with a child-resistant polypropylene cap and an induction seal.

Pack sizes:

Each bottle contains 30 tablets or 180 tablets.

Pack sizes of 1 bottle of 30 or 180 tablets without outer carton.

Not all pack sizes may be marketed.

Marketing Authorisation Holder:

Sanofi Winthrop Industrie

82 Avenue Raspail

94250 Gentilly

France

Manufacturer:

Genzyme Ireland Ltd.

IDA Industrial Park

Old Kilmeaden Road

Waterford

Ireland

Sanofi Winthrop Industrie

1 rue de la Vierge

Ambares et Lagrave

33565 Carbon Blanc cedex

France

You can request more information about this medicine from the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien/

Luxembourg/Luxemburg

Sanofi Belgium

Tél/Tel: + 32 2 710 54 00

Lietuva

Swixx Biopharma UAB

Tel. +370 5 236 91 40

????????

Swixx Biopharma EOOD

T?π: +359 2 4942480

Magyarország

SANOFI-AVENTIS Zrt

Tel: +36 1 505 0050

Ceská republika

sanofi-aventis, s.r.o.

Tel: +420 233 086 111

Malta

Sanofi S.r.l.

Tel: +39 02 39394275

Danmark

Sanofi A/S

Tlf: +45 45 16 70 00

Nederland

Sanofi B.V.

Tel: +31 20 245 4000

Deutschland

Sanofi-Aventis Deutschland GmbH

Tel: 0800 52 52 010

Tel. from abroad: +49 69 305 21 131

Norge

sanofi-aventis Norge AS

Tlf: + 47 67 10 71 00

Eesti

Swixx Bipharma OÜ

Tel. +372 6 40 10 30

Österreich

sanofi-aventis GmbH

Tel: + 43 1 80 185 - 0

Ελλάδα

sanofi-aventis Μονοπρ?σωπη AEBE

Τηλ: +30 210 900 1600

Polska

sanofi Sp. z o.o.

Tel.: +48 22 280 00 00

España

sanofi-aventis, S.A.

Tel: +34 93 485 94 00

Portugal

Sanofi – Produtos Farmacêuticos, Lda.

Tel: +351 21 35 89 400

France

Sanofi Winthrop Industrie

Tél : 0 800 222 555

Appel depuis l’étranger: +33 1 57 63 23 23

România

Sanofi Romania SRL

Tel: +40 (0) 21 317 31 36

Hrvatska

Swixx Biopharma d.o.o.

Tel: +385 1 2078500

Slovenija

Swixx Biopharma d.o.o.

Tel: +386 1 235 51 00

Ireland

sanofi-aventis Ireland Ltd T/A SANOFI

Tel: +353 (0) 1 4035 600

Slovenská republika

Swixx Biopharma s.r.o.

Tel.: +421 2 208 33 600

Ísland

Vistor hf.

Sími: +354 535 7000

Suomi/Finland

Sanofis Oy

Puh/Tel: + 358 201 200 300

Italia

Sanofi S.r.l.

Tel: 800.536 389

Sverige

Sanofi AB

Tel: +46 (0)8 634 50 00

Κúπρος

C.A. Papaellinas Ltd.

Τηλ: +357 22 741741

United Kingdom (Northern Ireland)

sanofi-aventis Ireland Ltd. T/A SANOFI

Tel: +44 (0) 800 035 2525

Latvija

Swixx Biopharma SIA

Tel: +371 6 616 47 50

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe